Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Ibrutinib Related Intermediates: (S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 4-Phenoxyphenylboronic Acid CAS 51067-38-0 Ibrutinib Intermediate N-2 CAS 330786-24-8 Ibrutinib Intermediate N-3 CAS 330792-70-6 Ibrutinib CAS 936563-96-1| Item | Specifications |
| Appearance | Off-White to Khaki Powder |
| Identification | HNMR, LC-MS |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <1.00% |
| Single Max. Impurity | <1.00% |
| Total Impurities | <1.00% |
| Heavy Metals (as Pb) | <20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Ibrutinib (CAS: 936563-96-1) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| Synonyms | Ibrutinib intermeidate N-2; Ibrutinib Deacryloylpiperidine; Ibrutinib Impurity 8; 5-(4-Phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine |
| CAS Number | 330786-24-8 |
| CAT Number | RF-PI1377 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C17H13N5O |
| Molecular Weight | 303.32 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS: 330786-24-8) is a useful synthetic intermediate in the synthesis of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.
